Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Statins effectively lower low-density lipoprotein (LDL) cholesterol and reduce cardiovascular (CV) events.
• Residual CV risk persists despite high-dose statin therapy, and statin intolerance affects many patients.
• Ezetimibe, an intestinal cholesterol absorption inhibitor, showed initial promise but failed to demonstrate CV outcome benefits in early trials.

Purpose of the Study:

• To evaluate the efficacy of ezetimibe as an add-on therapy to statins in reducing cardiovascular outcomes.
• To assess the benefits of combination therapy in diverse patient populations and its impact on biomarkers and plaque progression.

Main Methods:

• The study involved a large, well-designed clinical trial (IMPROVE-IT) assessing ezetimibe added to statin therapy.
• Patient outcomes were tracked across various demographics including sex, age, and comorbidities like chronic kidney disease (CKD) and diabetes mellitus.
• Biomarker changes and plaque regression were monitored as secondary endpoints.

Main Results:

• Ezetimibe added to statin therapy unequivocally demonstrated a reduction in cardiovascular outcomes.
• Benefits were observed across all subgroups, including elderly patients, those with CKD, diabetes mellitus, and prior coronary artery bypass grafting (CABG).
• Ezetimibe reduced CV biomarkers and induced plaque regression, similar to statins.

Conclusions:

• Ezetimibe is now established as a valuable add-on therapy to statins for patients not achieving LDL goals or not tolerating statin monotherapy.
• Combination therapy with ezetimibe and statins demonstrates excellent safety and efficacy.
• Major guidelines now endorse ezetimibe as part of dyslipidemia management, confirming its role in improving cardiovascular outcomes.